Ardelyx, Inc. Appoints Sue Hohenleitner as Chief Financial Officer, Effective November 4, 2025

Ardelyx appoints Sue Hohenleitner as Chief Financial Officer effective November 4, 2025, bringing extensive financial leadership experience.

Quiver AI Summary

Ardelyx, Inc. announced the appointment of Sue Hohenleitner as Chief Financial Officer (CFO), effective November 4, 2025. Hohenleitner brings over 30 years of experience in corporate finance, strategic planning, and operations, and has a strong track record in driving organizational transformation and growth in the biopharmaceutical sector. Previously, she served as Vice President and CFO of Johnson & Johnson's Innovative Medicine North America, where she managed financial strategies for a $36 billion business. Ardelyx's CEO, Mike Raab, praised her visionary leadership and strategic insights, which will be crucial as the company seeks to expand its commercial success. Hohenleitner expressed her enthusiasm for joining Ardelyx, highlighting the importance of developing new medicines to meet patient needs. She will take over the CFO role after Ardelyx's third-quarter financial reporting, following current CFO Justin Renz's transition.

Potential Positives

Appointment of Sue Hohenleitner as CFO brings over 30 years of financial leadership experience, enhancing the company's financial strategy and operational excellence.
Ms. Hohenleitner’s proven track record in driving organizational transformation and building financial strength is expected to accelerate Ardelyx's growth and momentum.
The company's focus on expanding commercial success with first-in-class medicines positions Ardelyx for long-term growth and innovation, potentially benefiting patients and shareholders.

Potential Negatives

Appointment of a new CFO could suggest potential instability or changes within the company's financial leadership structure.
The timing of the new CFO's appointment following the third quarter financial reporting may indicate challenges in the company's financial performance.
The reliance on a single individual's experience from a previous employer may raise concerns about the company's ability to foster internal leadership and innovation.

FAQ

Who is the new CFO of Ardelyx?

Sue Hohenleitner has been appointed as Chief Financial Officer of Ardelyx, effective November 4, 2025.

What experience does Sue Hohenleitner bring to Ardelyx?

Ms. Hohenleitner has over 30 years of experience in corporate finance and strategic planning across various therapeutic areas.

When will Sue Hohenleitner start her role as CFO?

She will assume the CFO position on November 4, 2025, after the completion of the third quarter financial reporting.

What were Sue Hohenleitner's previous roles?

Before Ardelyx, she served as the VP and CFO of Johnson & Johnson Innovative Medicine North America.

What is Ardelyx's mission?

Ardelyx aims to discover, develop, and commercialize innovative, first-in-class medicines addressing significant unmet medical needs.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$ARDX Insider Trading Activity

$ARDX insiders have traded $ARDX stock on the open market 19 times in the past 6 months. Of those trades, 4 have been purchases and 15 have been sales.

Here’s a breakdown of recent trading of $ARDX stock by insiders over the last 6 months:

DAVID M MOTT has made 4 purchases buying 881,377 shares for an estimated $3,403,196 and 0 sales.
MICHAEL RAAB (President & CEO) has made 0 purchases and 3 sales selling 134,170 shares for an estimated $639,248.
LAURA A WILLIAMS (Chief Patient Officer) has made 0 purchases and 4 sales selling 92,682 shares for an estimated $553,025.
ERIC DUANE FOSTER (Chief Commercial Officer) has made 0 purchases and 2 sales selling 17,815 shares for an estimated $101,034.
MIKE KELLIHER (Chief Business Officer) has made 0 purchases and 2 sales selling 19,939 shares for an estimated $91,402.
JUSTIN A RENZ (Chief Financial Officer) has made 0 purchases and 2 sales selling 14,255 shares for an estimated $71,200.
ELIZABETH A GRAMMER (See Remarks) has made 0 purchases and 2 sales selling 11,833 shares for an estimated $59,102.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$ARDX Hedge Fund Activity

We have seen 107 institutional investors add shares of $ARDX stock to their portfolio, and 105 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JANUS HENDERSON GROUP PLC removed 9,919,066 shares (-39.7%) from their portfolio in Q2 2025, for an estimated $38,882,738
MILLENNIUM MANAGEMENT LLC added 5,197,967 shares (+80.4%) to their portfolio in Q2 2025, for an estimated $20,376,030
MARSHALL WACE, LLP added 2,866,843 shares (+34.2%) to their portfolio in Q2 2025, for an estimated $11,238,024
BLACKROCK, INC. added 2,799,200 shares (+15.6%) to their portfolio in Q2 2025, for an estimated $10,972,864
BANK OF AMERICA CORP /DE/ added 2,600,080 shares (+88.8%) to their portfolio in Q2 2025, for an estimated $10,192,313
JONES FINANCIAL COMPANIES LLLP added 1,832,320 shares (+16861.3%) to their portfolio in Q2 2025, for an estimated $7,182,694
JANE STREET GROUP, LLC removed 1,676,856 shares (-68.6%) from their portfolio in Q2 2025, for an estimated $6,573,275

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$ARDX Analyst Ratings

Wall Street analysts have issued reports on $ARDX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HC Wainwright & Co. issued a "Buy" rating on 06/18/2025
Citigroup issued a "Buy" rating on 05/02/2025

To track analyst ratings and price targets for $ARDX, check out Quiver Quantitative's $ARDX forecast page.

$ARDX Price Targets

Multiple analysts have issued price targets for $ARDX recently. We have seen 5 analysts offer price targets for $ARDX in the last 6 months, with a median target of $10.0.

Here are some recent targets:

Christopher Raymond from Piper Sandler set a target price of $9.0 on 08/06/2025
Laura Chico from Wedbush set a target price of $14.0 on 08/05/2025
Ryan Deschner from Raymond James set a target price of $12.0 on 08/05/2025
Matthew Caufield from HC Wainwright & Co. set a target price of $10.0 on 06/18/2025
Yigal Nochomovitz from Citigroup set a target price of $10.0 on 05/02/2025

Full Release

WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Sue Hohenleitner as Chief Financial Officer (CFO), effective November 4, 2025. Ms. Hohenleitner is a proven financial leader, bringing more than 30 years of experience in corporate finance, strategic planning, investor relations and operations across a variety of therapeutic areas and stages of development. She has a demonstrated track record of driving organizational transformation, building financial strength and driving sustainable growth across commercial and development-stage products. Ms. Hohenleitner most recently served as the Vice President and Chief Financial Officer of Johnson & Johnson (J&J) Innovative Medicine North America (NA), leading financial strategies for a $36 billion commercial business.

“I am thrilled to welcome Sue to the Ardelyx leadership team,” said Mike Raab, president and chief executive officer of Ardelyx. “Sue is an accomplished and visionary financial leader whose proven ability to execute growth strategies and drive operational excellence makes her an exceptional addition to our company. Her forward-thinking approach, strategic insight and deep understanding of our industry will be instrumental as we expand our commercial success and pursue new opportunities for growth. Sue’s leadership and financial discipline will help accelerate Ardelyx’s momentum, strengthen our foundation and position the company for long-term success, helping us to deliver meaningful value for patients, employees and shareholders alike.”

“I am very excited to join Ardelyx at this important time in its evolution,” said Ms. Hohenleitner. “With two first-in-class medicines helping patients and plans for expansion in the years ahead, I look forward to working with the team to shape strategic paths for long-term growth and innovation for patients everywhere, to develop the next generation of important medicines and to help patients who need our drugs the most.”

Prior to joining Ardelyx, Ms. Hohenleitner enjoyed a 28-year career at J&J where she led multiple finance organizations in areas such as supply chain, innovation, commercial, business development, investor relations, acquisitions and divestitures, and finance planning and analysis. As VP and CFO of J&J Innovative Medicine NA, Ms. Hohenleitner led a number of strategic initiatives that resulted in greater efficiencies, effectiveness and funding for growth. Ms. Hohenleitner was also a critical partner during the acquisition of two significant deals which resulted in successful commercial launches.

Ms. Hohenleitner is a Certified Public Accountant in the Commonwealth of Pennsylvania and a Certified Management Accountant. She earned a Bachelor of Science in Accounting from La Salle University and a Master of Business Administration from Villanova University. Ms. Hohenleitner was named a Top 25 CFO in Biotech by Business & Investing.

Ms. Hohenleitner will assume the CFO role on November 4, 2025 following the completion of Ardelyx’s third quarter 2025 financial reporting. Justin Renz, the current Chief Financial and Operations Officer, will continue in his role through the filing of Ardelyx’s Quarterly Report on Form 10-Q.

About Ardelyx
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA ^® (tenapanor) and XPHOZAH ^® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL ^® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter) , LinkedIn and Facebook .

Investor and Media Contact
Caitlin Lowie
[email protected]